Trying to turn 'natural killers' against cancer, Nkarta raises $114 million

Aiming to use so-called "natural killer" cells to rev up the immune system against cancer, Nkarta Therapeutics Inc. raised $114 million from a lineup of biotech and crossover investors that hints at an IPO.